Boston Scientific Corporation
Boston Scientific Corporation
Your view on BSX
Overview
What the company does, where it operates, and who runs it.
About Boston Scientific Corporation
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Michael F. Mahoney
- Headquarters
- 300 Boston Scientific Way, Marlborough, MA, US
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Michael F. Mahoney
- Headquarters
- 300 Boston Scientific Way, Marlborough, MA, US
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular.
The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems.
It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems.
In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies.
Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer.
The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Stock Data
Price chart, volume, and trading data.
What moved it
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Boston Scientific Corporation from FRC's valuation model, read against the market price. BSX last traded at $43.69, 18.5× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Boston Scientific Corporation. Starting points for Boston Scientific Corporation: P/E 18.5, EPS $2.41, beta 0.58 — an Medical - Devices name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Boston Scientific Corporation. Boston Scientific Corporation does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Boston Scientific Corporation. Trailing twelve-month EPS for Boston Scientific Corporation stands at $2.41. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$56.58
average of 24 firms, last 12 months
Analyst Ratings
- Strong Buy0
- Buy18
- Hold7
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $0.78 | $0.75 | $3.16 | $3.12 |
| Low estimate | $0.77 | $0.73 | $3.15 | $3.05 |
| High estimate | $0.79 | $0.80 | $3.17 | $3.21 |
| No. of analysts | 15 | 10 | 16 | 16 |
| Year-ago EPS | $0.80 | $0.80 | $1.94 | — |
| Growth | -3.1% | -6.7% | +63.0% | — |
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $5.18B | $5.06B | $20.97B | $20.79B |
| Low estimate | $5.13B | $4.86B | $20.91B | $20.50B |
| High estimate | $5.29B | $5.49B | $21.11B | $21.59B |
| No. of analysts | 15 | 10 | 21 | 21 |
| Year-ago revenue | $5.29B | $5.20B | $20.07B | — |
| Growth | -2.0% | -2.7% | +4.5% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga, Pulse 2.0; as of Nov 18, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Boston Scientific Corporation. Boston Scientific Corporation has reported as a listed company since 1992. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- ANGOAngioDynamics, Inc.Medical - Instruments & Supplies$495M
- ATRCAtriCure, Inc.Medical - Instruments & Supplies$2.8B
- CNMDCONMED CorporationMedical - Devices$1.5B
- CVRXCVRx, Inc.Medical - Devices$17M
- EWEdwards Lifesciences CorporationMedical - Devices$61.6B
- LIVNLivaNova PLCMedical - Devices$5.1B
- MDTMedtronic plcMedical - Devices$131.6B
- MMSIMerit Medical Systems, Inc.Medical - Instruments & Supplies$5.2B
More Medical - Devices companies
- NHNKFNihon Kohden CorporationOTC$2.4B
- NHNKYNihon Kohden CorporationOTC$3.7B
- NMRDNemaura Medical Inc.OTC$404
- NMTCNeuroOne Medical Technologies CorporationNASDAQ$7M
- NNOXNano-X Imaging Ltd.NASDAQ$25M
- NPCENeuroPace, Inc.NASDAQ$275M
- NSPRInspireMD, Inc.NASDAQ$28M
- NSYSNortech Systems IncorporatedNASDAQ$35M
- NUMDNu-Med Plus, Inc.OTC$1M
- NUWENuwellis, Inc.NASDAQ$413,060
- NVCRNovoCure LimitedNASDAQ$1.3B
- NVNOenVVeno Medical CorporationNASDAQ$4M
ETFs holding Boston Scientific Corporation
% of the fund
- VOOVanguard S&P 500 ETF$1.0T in assets0.09%
- VTIVanguard Total Stock Market ETF$689.2B in assets0.08%
- IVViShares Core SP 500 ETF$852.9B in assets0.10%
- SPYState Street SPDR S&P 500 ETF Trust$818.5B in assets0.10%
- HHL.TOHarvest Healthcare Leaders Income ETF$2.2B in assets4.77%
- IHIiShares US Medical Devices ETF$4.0B in assets3.91%
- FXHFirst Trust Health Care AlphaDEX Fund$1.2B in assets1.82%
- BAFEBrown Advisory Flexible Equity ETF$1.7B in assets1.72%
Largest holders first, then the funds most concentrated in BSX.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Boston Scientific Corporation, and how their positions are changing. At a $63.33B market value, institutional positions materially move Boston Scientific Corporation's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Boston Scientific Corporation executives and directors. Shares of Boston Scientific Corporation have traded between $85.98 and $109.50 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
About this section
U.S. Senate disclosures naming Boston Scientific Corporation. Boston Scientific Corporation is a $63.33B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
About this section
U.S. House of Representatives disclosures naming Boston Scientific Corporation. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Boston Scientific Corporation. Coverage tracks Boston Scientific Corporation within Medical - Devices (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Boston Scientific Corporation.